Nurse Ambassador Icon

Nurse Ambassadors can help your patients every step of the way during treatment

MAVYRET Nurse Ambassadors are here to help

Clipboard Icon

Pre-first fill

  • Help patients learn about HCV
  • Discuss treatment goals
  • Help understand the insurance process
Stethoscope Icon


  • Answer questions patients might have before starting treatment
  • Offer tips about staying on track with the treatment plan, as prescribed
Laptop Icon


Support patients in their journey post-treatment by explaining processes such as:

  • Relapse
  • Reinfection
  • The importance of a lab test at 12 weeks post-treatment

MAVYRET Nurse Ambassadors provide product support but do not provide medical advice and will direct patients to their healthcare professional for any medical advice or questions related to treatment decisions and plans.


Data as of May 10, 2018. Based on enrollments through April 30, 2018.

Enrolling in the Nurse Ambassador Program is now easier than ever

Paper Icon

In the office

One-page paper form sign-up is available: download it here

Phone Icon

By phone

Phone sign-up 1-877-628-9738

Laptop Icon


Registration is available at the Patient Website

A Nurse Ambassador will contact patients within one business day of enrolling in MAVYRET Patient Support.


MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.



WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.



  • MAVYRET is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation.
  • MAVYRET is contraindicated with atazanavir or rifampin.



Risk of Hepatic Decompensation/Failure in Patients with Evidence of Advanced Liver Disease

  • Postmarketing cases of hepatic decompensation/failure, some fatal, have been reported in patients treated with HCV NS3/4A protease inhibitor-containing regimens, including MAVYRET. The median time to onset for MAVYRET was 27 days. The majority had moderate or severe hepatic impairment prior to initiating therapy, including some with compensated cirrhosis at baseline but with a prior decompensation event. Rare cases were reported in patients without cirrhosis or with compensated cirrhosis; many of these patients had evidence of portal hypertension. In patients with compensated cirrhosis or evidence of advanced liver disease, perform hepatic laboratory testing as clinically indicated; and monitor for signs and symptoms of hepatic decompensation such as the presence of jaundice, ascites, hepatic encephalopathy, and variceal hemorrhage. Discontinue MAVYRET in patients who develop evidence of hepatic decompensation/failure.


Risk of Reduced Therapeutic Effect Due to Concomitant Use of MAVYRET with Certain Drugs

  • Carbamazepine, efavirenz, and St. John’s Wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect of MAVYRET. The use of these agents with MAVYRET is not recommended.



Most common adverse reactions observed with MAVYRET:

  • >10% of subjects: headache and fatigue